Effective March 2, 2022, the GT Biopharma, Inc. (Registrant) appointed Michael Breen as the Registrant's Interim Chief Executive Officer with an increase in his annual base compensation to $515,000. Gregory Berk, M.D. ceased serving as the Registrant's Interim Chief Executive Officer, but will continue to serve as the Registrant's President of Research & Development and Chief Medical Officer, with a cost-of-living increase in his annual base compensation to $437,750.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.92 USD | +2.46% |
|
+1.04% | -61.83% |
06-07 | GT Biopharma, Inc. Announces CFO Changes | CI |
05-21 | Top Midday Decliners | MT |
1st Jan change | Capi. | |
---|---|---|
-61.83% | 6.3M | |
+51.63% | 796B | |
+41.51% | 628B | |
-5.10% | 358B | |
+19.90% | 331B | |
+9.95% | 301B | |
+17.66% | 244B | |
+3.39% | 228B | |
+10.75% | 214B | |
+6.99% | 165B |
- Stock Market
- Equities
- GTBP Stock
- News GT Biopharma, Inc.
- GT Biopharma, Inc. Announces CEO Changes